MASLD/MASH is a serious, chronic, progressive disease and will soon be the most common indication for liver transplantation and major driver of the development of liver cancer. Until recently there was no liver-directed therapy for MASH and the metabolic benefits of pharmacologic modification of body weight in the management of MASLD/MASH were underappreciated. This symposium will provide practical, interactive discussions of cardiometabolic pathophysiologic pathways, early identification and risk stratification, advances in treatment monitoring for disease progression, and long-term medical management, including the role of incretin agonists.
The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care
Join us to learn about advances in the treatment of MASH, including the basis for and benefits of pharmacologic strategies for modifying body weight.
Live
Broadcast
1.50 available credits
Information
November 16, 2024
08:00 PM - 09:30 PM PST
Virtual
Share this program on:
Details
Presenters
Comments
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Naim Alkhouri, MD, FAASLD, DABOM
Chief Medical Officer
Director of the Steatotic Liver Program
Chief of Transplant Hepatology
Arizona Liver Health
Phoenix, AZDr. Naim Alkhouri has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: 89Bio, Akero, Arbutus, AstraZeneca, Better Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Corcept, CymaBay, DSM, Galectin, Genentech, Genfit, Gilead, Healio, Hepagene, Intercept, Inventiva, Ionis, Ipsen, Madrigal, Merck, NGM, Noom, NorthSea, Novo Nordisk, Perspectum, Pfizer, Poxel, Viking, and Zydus.
Consulting Fees: 89Bio, AbbVie, Boehringer Ingelheim, Echosens, Fibronostics, Gilead, Intercept, Ipsen, Madrigal, NorthSea, Novo Nordisk, Perspectum, Pfizer, and Zydus.Faculty:
Nicholas Pennings, DO, DABOM, MFOMA, FACOFP, FAAFP
Director, Campbell University Health Center
Chair and Associate Professor of Family Medicine
Buies Creek, NCDr. Nicholas Pennings has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Abbott
Other: MedifastAmreen M. Dinani, MD, FRCPC
Associate Professor of Medicine
Gastroenterology
Duke University School of Medicine
Durham, NCDr. Amreen Dinani has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Madrigal Pharmaceuticals, Novo Nordisk
Research: GSK, Hanmi, Inventiva, Liver Cirrhosis Network, Madrigal Pharmaceuticals, NIDDKReviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals.
- Rosanne Strauss, PharmD, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Summarize the pathophysiologic rationale for using obesity pharmacotherapy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH)
- Apply recommendations for the treatment of patients with MASLD/MASH with GLP-1 RAs
- Devise a multidisciplinary plan to manage obesity in patients with MASLD/MASH
- Interpret data from clinical trials of emerging liver-directed therapies for MASLD/MASH
- Interpret data from clinical trials of emerging anti-obesity therapies for MASLD/MASH
Target Audience
This activity has been designed to meet the educational needs of hepatologists and advanced practice providers who work in hepatology practices, as well as gastroenterologists and all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with MASLD/MASH.
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Obesity Medicine Association. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity. 
Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-092-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.Commercial Support
This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals and Novo Nordisk, Inc.
Disclaimer
Presented for attendees of The Liver Meeting® 2024. This event/function is provided by Medtelligence and supported by Boehringer Ingelheim Pharmaceuticals and Novo Nordisk, Inc. This is not an official event/function of the American Association for the Study of Liver Diseases.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Details
Presenters
Comments
Overview
MASLD/MASH is a serious, chronic, progressive disease and will soon be the most common indication for liver transplantation and major driver of the development of liver cancer. Until recently there was no liver-directed therapy for MASH and the metabolic benefits of pharmacologic modification of body weight in the management of MASLD/MASH were underappreciated. This symposium will provide practical, interactive discussions of cardiometabolic pathophysiologic pathways, early identification and risk stratification, advances in treatment monitoring for disease progression, and long-term medical management, including the role of incretin agonists.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Naim Alkhouri, MD, FAASLD, DABOM
Chief Medical Officer
Director of the Steatotic Liver Program
Chief of Transplant Hepatology
Arizona Liver Health
Phoenix, AZDr. Naim Alkhouri has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: 89Bio, Akero, Arbutus, AstraZeneca, Better Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Corcept, CymaBay, DSM, Galectin, Genentech, Genfit, Gilead, Healio, Hepagene, Intercept, Inventiva, Ionis, Ipsen, Madrigal, Merck, NGM, Noom, NorthSea, Novo Nordisk, Perspectum, Pfizer, Poxel, Viking, and Zydus.
Consulting Fees: 89Bio, AbbVie, Boehringer Ingelheim, Echosens, Fibronostics, Gilead, Intercept, Ipsen, Madrigal, NorthSea, Novo Nordisk, Perspectum, Pfizer, and Zydus.Faculty:
Nicholas Pennings, DO, DABOM, MFOMA, FACOFP, FAAFP
Director, Campbell University Health Center
Chair and Associate Professor of Family Medicine
Buies Creek, NCDr. Nicholas Pennings has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Abbott
Other: MedifastAmreen M. Dinani, MD, FRCPC
Associate Professor of Medicine
Gastroenterology
Duke University School of Medicine
Durham, NCDr. Amreen Dinani has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Madrigal Pharmaceuticals, Novo Nordisk
Research: GSK, Hanmi, Inventiva, Liver Cirrhosis Network, Madrigal Pharmaceuticals, NIDDKReviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals.
- Rosanne Strauss, PharmD, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Summarize the pathophysiologic rationale for using obesity pharmacotherapy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH)
- Apply recommendations for the treatment of patients with MASLD/MASH with GLP-1 RAs
- Devise a multidisciplinary plan to manage obesity in patients with MASLD/MASH
- Interpret data from clinical trials of emerging liver-directed therapies for MASLD/MASH
- Interpret data from clinical trials of emerging anti-obesity therapies for MASLD/MASH
Target Audience
This activity has been designed to meet the educational needs of hepatologists and advanced practice providers who work in hepatology practices, as well as gastroenterologists and all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with MASLD/MASH.
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Obesity Medicine Association. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity. Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-092-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.Commercial Support
This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals and Novo Nordisk, Inc.
Disclaimer
Presented for attendees of The Liver Meeting® 2024. This event/function is provided by Medtelligence and supported by Boehringer Ingelheim Pharmaceuticals and Novo Nordisk, Inc. This is not an official event/function of the American Association for the Study of Liver Diseases.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Recommended
The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care – Chair’s Perspective
The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care – Chair’s Perspective
CME/CEThe Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care – Chair’s Perspective
0.25 credits
Naim Alkhouri, MD, FAASLD, DABOM
0.25 creditsFinally, I Can Take a Break from My Itch! Optimizing CKD-aP Treatment
Finally, I Can Take a Break from My Itch! Optimizing CKD-aP Treatment
CME/CEFinally, I Can Take a Break from My Itch! Optimizing CKD-aP Treatment
0.25 creditsJörg Latus, MD
0.25 creditsThe Shifting ATTR-CM Landscape: Early Diagnosis, Emerging Therapies & Personalized Care
The Shifting ATTR-CM Landscape: Early Diagnosis, Emerging Therapies & Personalized Care
CME/CEThe Shifting ATTR-CM Landscape: Early Diagnosis, Emerging Therapies & Personalized Care
0.50 creditsPablo Garcia-Pavia, MD, PhD
Francesco Cappelli, MD
0.50 creditsOptimizing Outcomes in Patients With IgAN: Novel Therapies and Evolving Guidelines
Optimizing Outcomes in Patients With IgAN: Novel Therapies and Evolving Guidelines
CME/CEOptimizing Outcomes in Patients With IgAN: Novel Therapies and Evolving Guidelines
0.25 creditsJürgen Floege, MD
Jonathan Barratt, PhD
0.25 credits